Re: getting her2+ER- bc to reexpress ER & consequences more complicated than thought
 

Has there been any studies for fulvestrant or exemestane (Aromasin) vs the non-steroidal AI's for non-metastatic HER2 breast cancer?

I"m also not clear on where fulvestrant fits into the picure vs tamoxifen, aromasin/femara, and aromasin, particularly with non-metastatic cancer. I think it was developed as a treatment for metastatic cancer, but is now branching into locally advanced cancer, etc?



Thanks

TRS

Re: getting her2+ER- bc to reexpress ER & consequences more complicated than thought
 

as far as I know fulvestrant only being used for metastatic bc (may be some trials going on for adjuvant, but I haven't heard them reported)

Re: getting her2+ER- bc to reexpress ER & consequences more complicated than thought
 

The following post in the Articles Forum contains a discussion of the presentation referenced by Lani above.

http://her2support.org/vbulletin/sho...eferrerid=1173

Hopeful

Re: getting her2+ER- bc to reexpress ER & consequences more complicated than thought
 

Thanks Hopeful. When I heard the talk I heard endocrine treatment insensitive (not partially insensitive). I perked up to be sure I heard right. Will try to see if that talk ends up online to listen again.

Re: getting her2+ER- bc to reexpress ER & consequences more complicated than thought
 

Lani,

I have a few questions about the trial that perhaps you can answer. I am including a link to the abstract from SABCS that accompanies the main subject of the article in the articles forum: http://www.abstracts2view.com/sabcs0...=SABCS09L_1839

Am I correct in that this was a European study? The results portion of the abstract says, "Between 2001 and January 2006, 9775 women were randomized to TEAM. In total, 99% of patients were ER+ and/or PgR+, 50% were node-negative, 44% underwent mastectomy, 68% received radiotherapy, and 36% received chemotherapy." There is no mention here of Herceptin. Do you know if any of the trial participants received Herceptin? I am thinking given the time frame and location the participants were drawn from, that they most likely did not.

Do I understand that those who were resistant are both Her2+ and Her3+, or was it either/or? When it is written with the slash, as it is in the article I posted, I am not sure how to interpret it.

Thanks for any light you can shed.

Hopeful